Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Xenon Pharmaceuticals Inc (XENE)

Xenon Pharmaceuticals Inc (XENE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,488,989
  • Shares Outstanding, K 83,190
  • Annual Sales, $ 7,500 K
  • Annual Income, $ -345,910 K
  • EBIT $ -373 M
  • EBITDA $ -371 M
  • 60-Month Beta 0.91
  • Price/Sales 466.42
  • Price/Cash Flow N/A
  • Price/Book 5.59

Options Overview Details

View History
  • Implied Volatility 55.41% (-118.19%)
  • Historical Volatility 118.53%
  • IV Percentile 34%
  • IV Rank 14.19%
  • IV High 176.33% on 02/20/26
  • IV Low 35.42% on 05/21/25
  • Expected Move (DTE 11) 5.16 (8.22%)
  • Put/Call Vol Ratio 2.63
  • Today's Volume 32,604
  • Volume Avg (30-Day) 6,430
  • Put/Call OI Ratio 0.85
  • Today's Open Interest 74,248
  • Open Int (30-Day) 45,583
  • Expected Range 57.60 to 67.92

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 22 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -1.19
  • Number of Estimates 7
  • High Estimate -1.07
  • Low Estimate -1.38
  • Prior Year -0.83
  • Growth Rate Est. (year over year) -43.37%

Price Performance

See More
Period Period Low Period High Performance
1-Month
40.74 +54.05%
on 02/11/26
62.91 -0.24%
on 03/09/26
+20.33 (+47.91%)
since 02/09/26
3-Month
39.29 +59.74%
on 01/20/26
62.91 -0.24%
on 03/09/26
+19.24 (+44.21%)
since 12/09/25
52-Week
26.74 +134.70%
on 04/09/25
62.91 -0.24%
on 03/09/26
+26.26 (+71.95%)
since 03/07/25

Most Recent Stories

More News
Xenon Pharmaceuticals Announces Proposed Public Offering

VANCOUVER, British Columbia and BOSTON, MA, March 09, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery,...

XENE : 62.76 (+49.64%)
Xenon Announces Positive Topline Data from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures (FOS)

X-TOLE2 met primary endpoint in both dose groups, including -53.2% median percent change (MPC) from baseline in monthly FOS frequency with 25 mg dose compared with -10.4% for placebo (p=0.000000000006)...

XENE : 62.76 (+49.64%)
Xenon to Announce Topline Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures on Monday, March 9, 2026

VANCOUVER, British Columbia and BOSTON, March 08, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical...

XENE : 62.76 (+49.64%)
Xenon Pharmaceuticals: Q4 Earnings Snapshot

Xenon Pharmaceuticals: Q4 Earnings Snapshot

XENE : 62.76 (+49.64%)
Xenon Reports Q4 and Full Year 2025 Financial Results and Provides Business Update

Phase 3 X-TOLE2 topline data for azetukalner in FOS expected first half of March 2026 Five additional Phase 3 studies of azetukalner continue to enroll in epilepsy and neuropsychiatry indications with...

XENE : 62.76 (+49.64%)
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

VANCOUVER, British Columbia and BOSTON, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical...

XENE : 62.76 (+49.64%)
Xenon Outlines Key Upcoming Milestones at the 2026 J.P. Morgan Healthcare Conference

Phase 3 X-TOLE2 topline data for azetukalner in FOS expected March 2026 followed by anticipated NDA submission in H2 2026 Five additional Phase 3 azetukalner studies continuing to enroll patients in...

XENE : 62.76 (+49.64%)
Xenon to Present at the 44th Annual J.P. Morgan Healthcare Conference

VANCOUVER, British Columbia and BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical...

XENE : 62.76 (+49.64%)
Xenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025

Monthly reductions in seizure frequency of 90.9% among participants treated for ≥48 months in the OLE, with 38% achieving ≥1 year of seizure freedom New X-TOLE OLE data analysis supports the ability...

XENE : 62.76 (+49.64%)
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

VANCOUVER, British Columbia and BOSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical...

XENE : 62.76 (+49.64%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 80%. The market has entered extreme overbought territory.

See More Share

Business Summary

Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development of medicines through the application of its proprietary discovery platform, which it refer to as Extreme Genetics. Xenon is developing proprietary product candidates for the treatment of both orphan...

See More

Key Turning Points

3rd Resistance Point 69.36
2nd Resistance Point 66.13
1st Resistance Point 64.45
Last Price 62.76
1st Support Level 59.54
2nd Support Level 56.31
3rd Support Level 54.63

See More

52-Week High 62.91
Last Price 62.76
Fibonacci 61.8% 49.09
Fibonacci 50% 44.83
Fibonacci 38.2% 40.56
52-Week Low 26.74

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar